Discussing Rheumatology: February 2023




Join Prof Iain McInnes as he reviews two interesting papers. In the first paper, Professor Maxime Dougados and colleagues shed some more light into the findings from the ORAL Surveillance trial, in comparison to those seen in the tofacitinib clinical development programme. And, in the second paper, Professor Kevin Winthrop and colleagues continue to report on safety by providing us with the latest findings from their review into opportunistic infections associated with JAK inhibitor treatment for RA.

Discussing AxSpA: Episode 5




Join Professors Atul Deodhar, Hideto Kameda, Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses new and emerging treatments for SpA. In particular it shines a light on treatments within axSpA. Following this, our second paper sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.

Discussing Rheumatology: January 2023




Join Prof Iain McInnes as he reviews two interesting papers. In the first paper the authors cover aspects from mean disease activity scores after tapering to radiographic outcomes and safety, to help ascertain whether it is possible to withdraw MTX while maintaining disease control. The second paper then goes on to also analyse MTX withdrawal data, but this time to evaluate the performance of disease activity metrics. Everything discussed is available in a more detailed slide format in the publications section at imidforum.com

Author Interview: Kevin Winthrop




Professor Kevin Winthrop, Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, from Oregon Health and Science University, USA, as well as a CSF Steering Committee member. In this edition Professor Winthrop discusses his recent paper 'Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.'

January 2023

Discussing PsA: Episode 5




Join Professor Philip Mease and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in December 2022. The first of our papers discusses the latest trial of a novel scoring system for inflammation and tissue damage, whilst the second paper compares adjunctive therapy usage in patients treated with IL-17A inhibitors.

Author Interview: Rebecca Haberman




Dr Rebecca Haberman from the Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, USA. In this edition Dr Haberman discusses her recent paper ‘Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.’